SDI Announces Participation of Berlex in Its Genomic Antibodies™ Initiative
News Apr 21, 2006
Under terms of this amended agreement, SDI will provide polyclonal and monoclonal Genomic Antibodies™ to Berlex.
Matthew H. Knight, President and CEO of Strategic Diagnostics commented, "We are extremely pleased to have a world-class company recognize the utility of Genomic Antibodies™."
"The SDI Genomic Antibodies™ process significantly reduces the time required to produce a custom antibody for Berlex and Genomic Antibodies™ are successfully produced to traditionally difficult antigen targets such as transmembrane proteins, membrane-associated proteins and highly conserved proteins, which will help Berlex to identify and market new pharmaceuticals more quickly."
Mr. Knight continued, "We are just beginning our commercial efforts for this exciting new offering and continue to interact with a number of significant companies and research initiatives."
"We believe we bring significant value to our customers by decreasing the time to deliver new diagnostics and or therapeutics to the market."
With machine learning systems now being used to determine everything from stock prices to medical diagnoses, it's never been more important to look at how they arrive at decisions. A new approach out of MIT demonstrates that the main culprit is not just the algorithms themselves, but how the data itself is collected.
International Conference on Cell and Structural biology
Jul 15 - Jul 16, 2019